tiprankstipranks
Advertisement
Advertisement
Ascentage Pharma: Undervalued Long-Term Oncology Leader Backed by Late-Stage Assets Olverembatinib and Lisaftoclax
PremiumRatingsAscentage Pharma: Undervalued Long-Term Oncology Leader Backed by Late-Stage Assets Olverembatinib and Lisaftoclax
2M ago
Ascentage Pharma Sets March 25, 2026 Date to Unveil 2025 Unaudited Results and Business Update
Premium
Company Announcements
Ascentage Pharma Sets March 25, 2026 Date to Unveil 2025 Unaudited Results and Business Update
2M ago
Ascentage Pharma Ramps Up Investor Outreach With Three U.S. Conferences
Premium
Company Announcements
Ascentage Pharma Ramps Up Investor Outreach With Three U.S. Conferences
2M ago
Ascentage Pharma initiated with a Buy at Rodman & Renshaw
PremiumThe FlyAscentage Pharma initiated with a Buy at Rodman & Renshaw
3M ago
Ascentage Pharma Wins FDA IND Clearance for BTK Degrader APG-3288 to Enter Global Phase I Trial
Premium
Company Announcements
Ascentage Pharma Wins FDA IND Clearance for BTK Degrader APG-3288 to Enter Global Phase I Trial
4M ago
Ascentage Pharma’s APG-3288 receives IND clearance from FDA
Premium
The Fly
Ascentage Pharma’s APG-3288 receives IND clearance from FDA
4M ago
Ascentage Pharma presents data from Phase Ib/II study of Lisaftoclax
PremiumThe FlyAscentage Pharma presents data from Phase Ib/II study of Lisaftoclax
5M ago
Ascentage Pharma presents data for Lisaftoclax at 2025 ASH
Premium
The Fly
Ascentage Pharma presents data for Lisaftoclax at 2025 ASH
5M ago
Ascentage Pharma initiated with an Outperform at Oppenheimer
Premium
The Fly
Ascentage Pharma initiated with an Outperform at Oppenheimer
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100